Health status, late effects and long‐term survivorship of allogeneic bone marrow transplantation: a retrospective study
Authors:
- 10 December 2013
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
- Vol. 44 (2) , 139-147
Abstract
Background: Survival after allogeneic haemopoietic stem cell transplantation (allo‐HSCT) has improved because of advancements in allo‐HSCT. Allo‐HSCT has been performed in Australia since the late 1970s. However, there are few published data about health problems of allo‐HSCT survivors in Australia.Aims: Identify health issues in long‐term survivors of allo‐HSCT in an Australian centre to manage better and prevent long‐term complications.Methods: The health records of all patients of allo‐HSCT in a single centre from January 2000 to December 2007 and survived beyond 2 years were assessed.Results: Ninety‐nine of the 200 allo‐HSCT patients survived beyond 2 years, and the median time from allo‐HSCT was 74 months. Twenty‐eight per cent died at a median of 37 months after allo‐HSCT because of relapsed malignancy (12%), stroke (1%), infection (3%), chronic graft versus host disease (9%), secondary malignancy (2%) and unknown cause (1%). Ninety‐one per cent reported one or more chronic health conditions. Health issues were chronic graft versus host disease (70%); respiratory (66%), ophthalmic (40%), bone (33%), and renal (26%) problems; and malignancies (14% skin, 3% solid organ). Seventy‐nine per cent resumed vocation at full or reduced capacity 2 years after allo‐HSCT. Clinicians identified 40% with quality of life (QOL) issues, but survivors’ self‐reported QOL was comparable with the general Australian population.Conclusion: This study shows that allo‐HSCT patients are living with high burdens of chronic diseases that warrant lifelong surveillance and engagement with healthcare. Structured, multi‐disciplinary care as recommended by published guidelines for allo‐HSCT survivors may reduce long‐term effects and improve their outcomes.Keywords
Funding Information
- Arrow Bone Marrow Transplant Foundation
- St Vincent's Haematology Research Funds
This publication has 30 references indexed in Scilit:
- Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS)Blood, 2011
- Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell TransplantationJournal of Clinical Oncology, 2011
- How I treat late effects in adults after allogeneic stem cell transplantationBlood, 2011
- Increased activity and improved outcome in unrelated donor haemopoietic cell transplants for acute myeloid leukaemia in Australia, 1992–2005Internal Medicine Journal, 2011
- Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor StudyBlood, 2010
- Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell TransplantationJournal of Clinical Oncology, 2010
- Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population RatesTransplantation and Cellular Therapy, 2009
- The Queensland cancer risk study: general population norms for the Functional Assessment of Cancer Therapy–General (FACT‐G)Psycho-Oncology, 2008
- Recommended Screening and Preventive Practices for Long-term Survivors after Hematopoietic Cell Transplantation: Joint Recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2006
- Recovery and Long-term Function After Hematopoietic Cell Transplantation for Leukemia or LymphomaJAMA, 2004